AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2463035 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) (Fragmin) 2500 anti-factor Xa units twice daily for 7 days
Number of subjects: 98
Study 2463035 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70 (Macrodex) 500 ml twice during the day of operation, followed by a single infusion of 500 ml on the first and again on the third postoperative day
Number of subjects: 98
Study 29032903 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot femoral nerve block
Number of subjects: 43
Study 29032903 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration anesthesia (Control)
Number of subjects: 43
Study 27285306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal vaginal ring (CVR)
Number of subjects: 50
Study 27285306 — intervention group
Group type: COMPARATOR
Intervention: Combined hormonal pills (CHP)
Number of subjects: 50
Study 25473945 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleophthalmologic group
Number of subjects: 169
Study 25473945 — intervention group
Group type: COMPARATOR
Intervention: Routine group
Number of subjects: 169
Study 25473945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 169
Study 23024246 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 139
Study 23024246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 19861236 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle third patellar tendon graft (PT)
Number of subjects: 50
Study 19861236 — intervention group
Group type: COMPARATOR
Intervention: Leeds-Keio synthetic graft (LK)
Number of subjects: 50
Study 18420320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermis-fat graft interposition after arthroplasty
Number of subjects: 17
Study 18420320 — intervention group
Group type: COMPARATOR
Intervention: Temporalis fascia interposition
Number of subjects: 17
Study 16838876 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum with sodium hexametaphosphate (4%)
Number of subjects: 54
Study 16838876 — intervention group
Group type: COMPARATOR
Intervention: No-gum group
Number of subjects: 54
Study 12619672 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT)
Number of subjects: 25
Study 12619672 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 25
Study 11050588 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% ajoene
Number of subjects: 70
Study 11050588 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ajoene
Number of subjects: 70
Study 11050588 — intervention group
Group type: COMPARATOR
Intervention: 1% terbinafine
Number of subjects: 70
Study 9255326 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchanges (PE)
Number of subjects: 32
Study 9255326 — intervention group
Group type: COMPARATOR
Intervention: Control group (CS without PE)
Number of subjects: 32
Study 1345694 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (10 mcg/kg.min for 1 hour)
Number of subjects: 50
Study 1345694 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus dobutamine (D+) for 9 consecutive days
Number of subjects: 50
Study 1345694 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (D-)
Number of subjects: 50
Study 3877290 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol ('Diprivan') 1.5 mg/kg
Number of subjects: 20
Study 3877290 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 2 mg/kg
Number of subjects: 20
Study 31860972 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-off accelerated corneal collagen crosslinking (CXL) with epithelial abrasion and 18 mW/cm ultraviolet A irradiation for 5 minutes
Number of subjects: 23
Study 31860972 — intervention group
Group type: COMPARATOR
Intervention: 5% NaCl hypertonic saline (HS) instillation
Number of subjects: 23
Study 27417000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (LCZ696)
Number of subjects: 8399
Study 27417000 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study 23582501 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH) 38±14.73mg/kg
Number of subjects: 341
Study 23582501 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 1.43±0.74mg/kg
Number of subjects: 341
Study 23582501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 341
Study 21736700 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselling promoting exclusive breast or formula feeding
Number of subjects: 17
Study 20687982 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol 400/10 microg
Number of subjects: 728
Study 20687982 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol 200/10 microg
Number of subjects: 728
Study 18588696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (exposed to biasing prompts)
Number of subjects: 163
Study 18588696 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to biasing prompts)
Number of subjects: 163
Study 16093575 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg daily for eight weeks)
Number of subjects: 15
Study 16093575 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 15
Study 16093575 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 15
Study 12814141 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (up to 3100 microg)
Number of subjects: 38
Study 12814141 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 38
Study 11043615 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 122
Study 11043615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 8785636 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 59
Study 8785636 — intervention group
Group type: COMPARATOR
Intervention: Bone Scintigraphy (BS)
Number of subjects: 59
Study 1338388 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg daily
Number of subjects: 97
Study 1338388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 4053114 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical history and simple bedside evaluation
Number of subjects: 698
Study 4053114 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum enzyme activity
Number of subjects: 698
Study 4053114 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐year survival
Number of subjects: 698
Study 4053114 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence and severity of congestive heart failure
Number of subjects: 698
Study 4053114 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of severe ventricular arrhythmias during initial hospitalization
Number of subjects: 698
Study 31437476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) for 8 weeks
Number of subjects: 26
Study 31437476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 26
Study 31437476 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 26
Study 29068818 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based mastery learning (SBML)
Number of subjects: 709
Study 29068818 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditionally trained residents)
Number of subjects: 709
Study 29068818 — intervention group
Group type: COMPARATOR
Intervention: Control group (pulmonary and IR referrals)
Number of subjects: 709
Study 26661717 — intervention group
Group type: EXPERIMENTAL
Intervention: MyMediHealth (MMH) - SMS reminders for 3 weeks
Number of subjects: 98
Study 26661717 — intervention group
Group type: COMPARATOR
Intervention: Control - action lists as part of usual care
Number of subjects: 98
Study 23850157 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-structured calcium phosphate ceramic
Number of subjects: 20
Study 22751087 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 23
Study 19856249 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-h single serum method using dual stable isotopes
Number of subjects: 19
Study 19856249 — intervention group
Group type: COMPARATOR
Intervention: 24-h urine method
Number of subjects: 19
Study 19856249 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 19
Study 18090695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 31
Study 18090695 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 31
Study 15671606 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban + Heparin (Group III)
Number of subjects: 160
Study 15671606 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban + Dalteparin (Group IV)
Number of subjects: 160
Study 15671606 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (Group I)
Number of subjects: 160
Study 15671606 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin alone (Group II)
Number of subjects: 160
Study 11547294 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) kallikrein inhibiting units)
Number of subjects: 55
Study 11547294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9595364 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 abnormal OGTT value
Number of subjects: 325
Study 9595364 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM
Number of subjects: 325
Study 9595364 — intervention group
Group type: COMPARATOR
Intervention: Control (normal OGTT)
Number of subjects: 325
Study 7996404 — intervention group
Group type: EXPERIMENTAL
Intervention: Can-opener capsulotomy
Number of subjects: 57
Study 7996404 — intervention group
Group type: EXPERIMENTAL
Intervention: Retained anterior capsule flap
Number of subjects: 57
Study 7996404 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both techniques
Number of subjects: 57
Study 2887623 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate plus 0.025% xylometazoline
Number of subjects: 40
Study 2887623 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 40
Study 29914463 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention consisting of two MI sessions offered by caseworkers at the Norwegian Labor and Welfare Service (NAV)
Number of subjects: 0
Study 29914463 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 0
Study 29914463 — intervention group
Group type: COMPARATOR
Intervention: Group that receives two extra sessions without MI content (to control for attentional bias)
Number of subjects: 0
Study 29914463 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 0
Study 26733274 — intervention group
Group type: EXPERIMENTAL
Intervention: IV PCA + SSNB + ANB
Number of subjects: 114
Study 26733274 — intervention group
Group type: COMPARATOR
Intervention: IV PCA + SSNB
Number of subjects: 114
Study 26733274 — intervention group
Group type: COMPARATOR
Intervention: IV PCA (only PCA)
Number of subjects: 114
Study 23563646 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pressure MCSs (23-32 mmHg, group B)
Number of subjects: 88
Study 23563646 — intervention group
Group type: COMPARATOR
Intervention: Low pressure MCSs (18-21 mmHg, group A)
Number of subjects: 88
Study 24212227 — intervention group
Group type: EXPERIMENTAL
Intervention: Recanalization (RC) with 20 G endodiathermy bipolar probe connected to a 7 W diathermy followed by bicanalicular intubation
Number of subjects: 209
Study 24212227 — intervention group
Group type: COMPARATOR
Intervention: Standard external dacryocystorhinostomy (DCR)
Number of subjects: 209
Study 21515812 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dosing of [D(10)]phenanthrene (10 μg)
Number of subjects: 16
Study 21515812 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of [D(10)]phenanthrene (10 μg)
Number of subjects: 16
Study 18070096 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 60
Study 18070096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16854753 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 275
Study 16854753 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 275
Study 14691666 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed circuit system
Number of subjects: 19
Study 14691666 — intervention group
Group type: COMPARATOR
Intervention: Open circuit system
Number of subjects: 19
Study 11066462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutrition education letters
Number of subjects: 72
Study 11066462 — intervention group
Group type: COMPARATOR
Intervention: Standardized nutrition education letters
Number of subjects: 72
Study 9062631 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adsorbed Parietaria-pollen allergoid (Allergovit)
Number of subjects: 40
Study 9062631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8383688 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 504
Study 8383688 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg
Number of subjects: 504
Study 8383688 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg (additional doses allowed)
Number of subjects: 504
Study 8383688 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg (additional doses allowed)
Number of subjects: 504
Study 8383688 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (both doses)
Number of subjects: 504
Study 6403935 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 7
Study 6403935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6403935 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 7
Study 6403935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 7
Study 6403935 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 7
Study 6403935 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (in preliminary study)
Number of subjects: 7
Study 31957251 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 0
Study 31957251 — intervention group
Group type: COMPARATOR
Intervention: WBI/WBI-chemotherapy
Number of subjects: 0
Study 31184015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical sodium hyaluronate 50 ml 1 time per week for 12 weeks
Number of subjects: 59
Study 31184015 — intervention group
Group type: COMPARATOR
Intervention: Intravesical sodium hyaluronate combined with oral chondroitin sulfate 0.39 g (2 capsules 3 times a day) for 12 weeks
Number of subjects: 59
Study 29729425 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 412
Study 29729425 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood stress
Number of subjects: 412
Study 29729425 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing 3 to 4 hardships
Number of subjects: 412
Study 27589414 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50 mg/day
Number of subjects: 32
Study 27589414 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 100 mg/day
Number of subjects: 32
Study 27589414 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 200 mg/day
Number of subjects: 32
Study 27589414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 27589414 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 32
Study 24576465 — intervention group
Group type: EXPERIMENTAL
Intervention: Television (TV) watching
Number of subjects: 20
Study 24576465 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational computer use
Number of subjects: 20
Study 24576465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary video game (VG) play
Number of subjects: 20
Study 22207696 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-channel multichannel compression (MCC)
Number of subjects: 3
Study 22207696 — intervention group
Group type: COMPARATOR
Intervention: Control (linear) condition
Number of subjects: 3
Study 20530398 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated implementation strategies for PCMH
Number of subjects: 0
Study 20530398 — intervention group
Group type: COMPARATOR
Intervention: Self-directed implementation strategies for PCMH
Number of subjects: 0
Study 20530398 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical record audits
Number of subjects: 0
Study 20530398 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient surveys
Number of subjects: 0
Study 20530398 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician and staff surveys
Number of subjects: 0
Study 20530398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnographic observations
Number of subjects: 0
Study 17572925 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 33
Study 17572925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 16618361 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgE measurement at 12 months of age
Number of subjects: 715
Study 16618361 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgE measurement at 18 months of age
Number of subjects: 715
Study 16618361 — intervention group
Group type: COMPARATOR
Intervention: Skin prick test positivity to any allergen
Number of subjects: 715
Study 15284972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-incision (group 1)
Number of subjects: 42
Study 15284972 — intervention group
Group type: COMPARATOR
Intervention: Standard incision (group 2)
Number of subjects: 42
Study 11098350 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 8803359 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment + Book (30‐min telephone motivational interview plus book by mail)
Number of subjects: 155
Study 8803359 — intervention group
Group type: COMPARATOR
Intervention: Book by mail
Number of subjects: 155
Study 8803359 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment + Book
Number of subjects: 155
Study 1814902 — intervention group
Group type: EXPERIMENTAL
Intervention: Azoran (1000 mg)
Number of subjects: 14
Study 1814902 — intervention group
Group type: COMPARATOR
Intervention: Imuran (imported formulation)
Number of subjects: 14
Study 6662172 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 31 micrograms
Number of subjects: 12
Study 6662172 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 63 micrograms
Number of subjects: 12
Study 6662172 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 125 micrograms
Number of subjects: 12
Study 6662172 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 250 micrograms
Number of subjects: 12
Study 6662172 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 2 X 250 micrograms
Number of subjects: 12
Study 6662172 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline sulphate 5 X 250 micrograms
Number of subjects: 12
Study 31865897 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat endovascular thrombectomy (rEVT)
Number of subjects: 3928
Study 30429276 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAAs)
Number of subjects: 275
Study 30429276 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched individuals without ALS)
Number of subjects: 275
Study 26381076 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led care
Number of subjects: 1653
Study 26381076 — intervention group
Group type: COMPARATOR
Intervention: Consultant-led care
Number of subjects: 1653
Study 24662904 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-menopausal women
Number of subjects: 48
Study 24662904 — intervention group
Group type: COMPARATOR
Intervention: Pre-menopausal women
Number of subjects: 48
Study 21527615 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography for verifying tracheal tube placement
Number of subjects: 150
Study 17559360 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication
Number of subjects: 80
Study 17559360 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial elimination of H. pylori infection
Number of subjects: 80
Study 17559360 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication
Number of subjects: 80
Study 17559360 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial elimination
Number of subjects: 80
Study 17559360 — intervention group
Group type: COMPARATOR
Intervention: Failed eradication
Number of subjects: 80
Study 17139602 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with endothelin-receptor inhibitors, phosphodiesterase-5 inhibitors, and prostanoids
Number of subjects: 0
Study 17139602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (e.g., Imatinib)
Number of subjects: 0
Study 17139602 — intervention group
Group type: EXPERIMENTAL
Intervention: Activators and simulators of soluble guanylyl cyclase
Number of subjects: 0
Study 14663808 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8% tranexamic acid mouthwash (10 mL, 4 times a day for 7 days postoperatively)
Number of subjects: 49
Study 14663808 — intervention group
Group type: COMPARATOR
Intervention: Autologous fibrin glue (intraoperatively)
Number of subjects: 49
Study 11198496 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric crying facies (ACF)
Number of subjects: 5532
Study 8926685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense preradiation chemotherapy
Number of subjects: 133
Study 1290924 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg/day for 4 days)
Number of subjects: 11
Study 1290924 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin
Number of subjects: 11
Study 6585734 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐mg prostaglandin E2 vaginal suppository
Number of subjects: 85
Study 6585734 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 85